

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087680 A1

(51) International Patent Classification⁷: **C07D 239/84**,
A61K 31/517, A61P 25/28, 25/20, 25/22, 25/24, 3/04,
9/12, 9/00, 25/16, 25/08, 3/00

Street, San Diego, CA 92127 (US). **CASPER, Martin**
[US/US]; 6341 Peach Way, San Diego, CA 92130 (US).
KRAMER, Bryan, A. [US/US]; 8863 Duncan Road, San
Diego, CA 92126 (US).

(21) International Application Number:

PCT/JP2004/004554

(74) Agents: **ASAMURA, Kiyoshi** et al.; Room 331, New
Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku,
Tokyo 100-0004 (JP).

(22) International Filing Date: 30 March 2004 (30.03.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/458,424

31 March 2003 (31.03.2003) US

(71) Applicants (for all designated States except US): **TAISHO
PHARMACEUTICAL CO., LTD.** [JP/JP]; 24-1, Takata
3-chome, Toshima-ku, Tokyo 170-8633 (JP). **ARENA
PHARMACEUTICALS INC.** [US/US]; 6166 Nancy
Ridge Drive, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SEKIGUCHI,**
Yoshinori [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd.,
24-1, Takata 3-chome, Toshima-ku, Tokyo 170-8633 (JP).
KANUMA, Kosuke [JP/JP]; c/o Taisho Pharmaceutical
Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo
170-8633 (JP). **OMODERA, Katsunori** [JP/JP]; c/o
Taisho Pharmaceutical Co., Ltd., 24-1, Takata 3-chome,
Toshima-ku, Tokyo 170-8633 (JP). **BUSUJIMA, Tsuyoshi**
[JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takata
3-chome, Toshima-ku, Tokyo 170-8633 (JP). **TRAN,**
Thuy-Anh [US/US]; 4833 Fairport Way, San Diego, CA
92130 (US). **HAN, Sangdon** [KR/US]; 9953 Fieldthorn

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF



(I)

(57) Abstract: The present invention relates to novel compounds of Formula (I):
which act as MCH receptor antagonists. These compositions are useful in phar-
maceutical compositions whose use includes prophylaxis or treatment of improv-
ing memory function, sleeping and arousal, anxiety, depression, mood disorders,
seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease,

hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including
manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders
and dyskinesias including Parkinson's disease, epilepsy, and addiction.